FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

REICIN ALISE
2. Issuer Name and Ticker or Trading Symbol

CELGENE CORP /DE/ [ CELG ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
PRES., GLOBAL CLINICAL DEV.
(Last)          (First)          (Middle)

C/O CELGENE CORPORATION, 86 MORRIS AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

11/1/2019
(Street)

SUMMIT, NJ 07901
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/1/2019    M    11903  A $0 (1)(2) 11903  D 
 
Common Stock  11/1/2019    F    4722  D $108.53  7181  D 
 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit   (1)(2) 11/1/2019    M        11903    (1)  (1) Common Stock  11903  $0 (3) 23807 (4) D 
 

Explanation of Responses:
(1)  One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock.
(2)  Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
(3)  The restricted stock units were issued pursuant to the Company's 2014 Equity Incentive Plan.
(4)  The remainder of the restricted stock units will vest in two installments as follows: 11,903 shares on November 1,2020 and 11,904 shares on November 1, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
REICIN ALISE
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT, NJ 07901


PRES., GLOBAL CLINICAL DEV.

Signatures
/s/ Jonathan Biller, Attorney-in-Fact 11/4/2019
**Signature of Reporting Person Date


Celgene (NASDAQ:CELG)
過去 株価チャート
から 11 2024 まで 12 2024 Celgeneのチャートをもっと見るにはこちらをクリック
Celgene (NASDAQ:CELG)
過去 株価チャート
から 12 2023 まで 12 2024 Celgeneのチャートをもっと見るにはこちらをクリック

ニュース - Celgene Corp /de/

Real-Time news about Celgene Corporation (ナスダック市場): 0 recent articles

その他のCelgene Corp /de/ニュース記事

最近閲覧した銘柄

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.